Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With or Without Panitumumab in Patients With Advanced Urothelial Carcinoma: Multicenter, Randomized, French Unicancer GETUG/AFU 19 Study

•Epidermal growth factor receptor (EGFR) overexpression is frequent and associated with poor outcome in urothelial carcinoma (UC).•A randomized phase II study looked at whether the EGRF inhibition by monoclonal antibody panitumumab could increase the efficacy of standard chemotherapy in advanced UC....

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Clinical genitourinary cancer 2021-08, Vol.19 (4), p.e216-e222
Hauptverfasser:	Culine, Stéphane, Fléchon, Aude, Gravis, Gwenaelle, Roubaud, Guilhem, Loriot, Yohann, Joly, Florence, Barthélémy, Philippe, Assaf, Elias, Mahammedi, Hakim, Beuzeboc, Philippe, Houédé, Nadine, Rolland, Frédéric, Guillot, Aline, Gross-Goupil, Marine, Spano, Jean-Philippe, Tartas, Sophie, Deblock, Mathilde, Chevreau, Christine, Serrate, Camille, Manduzio, Hélène, Habibian, Muriel, Thézénas, Simon, Allory, Yves
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Combined Chemotherapy Protocols Cancer Carcinoma, Transitional Cell Chemotherapy Cisplatin Doxorubicin Epidermal growth factor receptor Humans Life Sciences Methotrexate Monoclonal antibody Panitumumab Transitional cell carcinoma Urinary Bladder Neoplasms Vinblastine
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!